AAO Updates HCQ Retinopathy Guidance
Updated recommendations emphasize dosing limits and screening for toxicity risk.
-
By
-
Andrea Surnit
-
April 23, 2026
-
Clinical Scorecard: AAO Updates HCQ Retinopathy Guidance
At a Glance
| Category | Detail |
|---|
| Condition | Hydroxychloroquine Retinopathy |
| Key Mechanisms | Risk of retinopathy associated with hydroxychloroquine use, influenced by dosing and screening practices. |
| Target Population | Long-term users of hydroxychloroquine, predominantly female, with conditions such as systemic lupus erythematosus and rheumatoid arthritis. |
| Care Setting | Ophthalmology clinics and primary care settings. |
Key Highlights
- Risk of toxicity is less than 1% within 5 years at recommended dosing.
- Annual screening is advised, with baseline screening recommended near treatment initiation.
- Risk of toxicity increases with higher doses and longer duration of use.
- New technologies like AI-based imaging analysis show potential but are not yet validated for routine use.
- Retinopathy detection at mild stages is crucial to prevent progression.
Guideline-Based Recommendations
Diagnosis
- Baseline screening with optical coherence tomography (OCT) and fundus autofluorescence (FAF) is recommended.
Management
- Maintain dosing at no more than 5 mg/kg/day of real body weight.
Monitoring & Follow-up
- Annual screening during therapy; may be deferred for up to 5 years in patients without major risk factors.
Risks
- Increased risk of toxicity in patients with renal disease, older age at treatment initiation, or concurrent use of tamoxifen.
Patient & Prescribing Data
Patients receiving hydroxychloroquine for chronic conditions.
With proper dosing and screening, most patients can safely use HCQ for decades.
Clinical Best Practices
- Utilize OCT and FAF as primary screening tools.
- Implement annual monitoring for long-term HCQ users.
- Educate patients on the importance of adherence to dosing and screening recommendations.
Related Resources & Content
